{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:52:41Z","timestamp":1741067561267,"version":"3.38.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"1-2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Generic Medicines"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p> European pharmaceutical manufacturers are finding it increasingly difficult to compete with pharmaceutical players established outside Europe. As a result, Europe has witnessed the migration of jobs, R&amp;D centres and production units to other parts of the world, leading to the gradual deindustrialization of the European pharmaceutical sector. This paper seeks to address this concern by showing that minor adjustments in the Intellectual Property rights regime in Europe may lead to a relevant impact on fostering innovation, high-tech employment and reindustrialization, thus contributing to the competitiveness of the European industrial pharmaceutical activity and to the European economic recovery. Two major pragmatic measures are discussed and evaluated: the manufacturing provision and the export provision. As illustrated below, over the next 9 years, the European ratification of the manufacturing provision and of the export provision could potentially represent a \u20ac3,339 million business volume (at ex-work prices); generate up to 8,890 new direct jobs and 35,560 new indirect jobs; and potentially generate the investment associated to the enhancement of manufacturing capacity equivalent to the creation of 37 new medium-sized pharmaceutical enterprises. It should be emphasized that for this study only 73% of the European market ( manufacturing provision) and 11% of the non-European market ( export provision) was considered for calculation purposes. Hence, these already impressive numbers are just a sample of the full potential of these Provisions. <\/jats:p>","DOI":"10.1177\/1741134314553606","type":"journal-article","created":{"date-parts":[[2014,10,10]],"date-time":"2014-10-10T03:44:02Z","timestamp":1412912642000},"page":"35-47","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Manufacturing and export provisions: Impact on the competitiveness of European pharmaceutical manufacturers and on the creation of jobs in Europe"],"prefix":"10.1177","volume":"11","author":[{"given":"Vanda","family":"Vicente","sequence":"first","affiliation":[{"name":"Researcher, Bluepharma Ind\u00fastria Farmac\u00eautica, SA, Portugal"}]},{"given":"S\u00e9rgio","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Professor at Faculty of Pharmacy, University of Coimbra, Portugal"},{"name":"VP of Bluepharma, Ind\u00fastria Farmac\u00eautica, SA, Portugal"}]}],"member":"179","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"key":"bibr1-1741134314553606","unstructured":"European Commission. Europe 2020, http:\/\/ec.europa.eu\/europe2020\/index_en.htm (2010, accessed 9 December 2013)."},{"key":"bibr2-1741134314553606","unstructured":"Sheppard A. Generic medicines: essential contributors to the long-term health of society. Sector sustainability challenges in Europe. Report, IMS Health, UK, 2010."},{"key":"bibr3-1741134314553606","unstructured":"European Generic Medicines Association. Generic medicines: a cornerstone of EU healthcare policy, http:\/\/www.egagenerics.com\/images\/EGA_factsheet_09.pdf (2011, accessed 9 December 2013)."},{"key":"bibr4-1741134314553606","doi-asserted-by":"publisher","DOI":"10.1177\/1741134312441107"},{"key":"bibr5-1741134314553606","unstructured":"Generics and Biosimilars Initiative. Challenges facing generic manufacturers in Europe, http:\/\/www.gabionline.net\/Reports\/Challenges-facing-generic-manufacturers-in-Europe\/(highlight)\/challenges%20facing%20generic (2010, accessed 12 December 2013)."},{"key":"bibr6-1741134314553606","unstructured":"Official website of the European Union. EUR-Lex. Council Regulation (EEC) No 1768\/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products, http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CELEX:31992R1768:EN:HTML (1992, accessed 12 December 2013)."},{"key":"bibr7-1741134314553606","unstructured":"European Generic Medicines Association. Generic Medicines, Data Exclusivity and Patents, http:\/\/www.egagenerics.com\/images\/factsheet\/EGA_factsheet_03.pdf (2010, accessed 12 December 2013)."},{"key":"bibr8-1741134314553606","unstructured":"European Generic Medicines Association. The Future of Pharmaceuticals: Generic Medicines Enhancing Pharmaceutical Competition and Ensuring Healthcare Sustainability, http:\/\/198.170.119.137\/doc\/ega_FuturePharmaceuticals.pdf (2007, accessed 12 December 2013)."},{"key":"bibr9-1741134314553606","doi-asserted-by":"crossref","unstructured":"Muzaka V. Intellectual property protection and European \u2018competitiveness\u2019. Rev Int Political Econ. Epub ahead of print 17 December 2012. DOI: 10.1080\/09692290.2012.724436.","DOI":"10.1080\/09692290.2012.724436"},{"key":"bibr10-1741134314553606","first-page":"1","volume":"2","author":"Pochet P","year":"2010","journal-title":"ETUI Policy Brief, European Social Policy"},{"key":"bibr11-1741134314553606","unstructured":"World Trade Organization. Agreement on Trade-Related Aspects of Intellectual Property Rights, http:\/\/www.wto.org\/english\/tratop_e\/trips_e\/trips_e.htm (1994, accessed 12 December 2013)."},{"key":"bibr12-1741134314553606","unstructured":"European Commission. What is an SME? http:\/\/ec.europa.eu\/enterprise\/policies\/sme\/facts-figures-analysis\/sme-definition\/ (2003, accessed 12 December 2013)."},{"key":"bibr13-1741134314553606","unstructured":"European Generic Medicines Association. DG Trade \u2013 Overview of the EU's Pharmaceuticals Sector, http:\/\/www.egagenerics.com\/images\/factsheet\/tradoc_148988.pdf (2011, accessed 12 December 2013)."},{"key":"bibr14-1741134314553606","unstructured":"The Association of the British Pharmaceutical Industry. The pharmaceutical industry\u2019s contribution to the UK economy and beyond, http:\/\/www.abpi.org.uk\/about-us\/objectives\/Documents\/UK%20economy%20and%20beyond.pdf (2010, accessed 12 December 2013)."},{"key":"bibr15-1741134314553606","unstructured":"Economic Commission for Latin America and the Caribbean (ECLAC). India and Latin America and the Caribbean \u2013 Opportunities and challenges in trade and investment relations, http:\/\/www.iadb.org\/intal\/intalcdi\/PE\/2012\/09631.pdf (2011, accessed 03 June 2014)."},{"key":"bibr16-1741134314553606","unstructured":"Asociaci\u00f3n Latinoamericana de Industrias Farmac\u00e9uticas. La Industria Farmaceutica Latinoamericana, http:\/\/www.alifar.org\/posts\/index\/4\/name:El-Mercado-Farmaceutico (2011, accessed 12 December 2013)."},{"key":"bibr17-1741134314553606","unstructured":"European Commission. European Commission pharmaceutical sector inquiry preliminary report \u2013 Comments from the EPO, http:\/\/ec.europa.eu\/competition\/consultations\/2009_pharma\/european_patent_office.pdf (2009, accessed 12 December 2013)."},{"key":"bibr18-1741134314553606","unstructured":"World Trade Organization. Canada\u2009-\u2009Patent Protection of Pharmaceutical Products\u2009-\u2009Complaint by the European Communities and their Member States \u2013 Report of the Panel, https:\/\/docs.wto.org\/dol2fe\/Pages\/FE_Search\/FE_S_S006.aspx?Query=(@Symbol=%20wt\/ds114\/r*%20not%20rw*)&Language=ENGLISH&Context=FomerScriptedSearch&languageUIChanged=true# (2000, accessed 12 December 2013)."},{"key":"bibr19-1741134314553606","unstructured":"Official website of the European Union. EUR-Lex. Regulation (EC) No 1901\/2006 of The European Parliament and of The Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004, http:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=CONSLEG:2006R1901:20070126:EN:PDF (2006, accessed 12 December 2013)."}],"container-title":["Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1741134314553606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1741134314553606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1741134314553606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:24:56Z","timestamp":1741029896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1741134314553606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":19,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1177\/1741134314553606"],"URL":"https:\/\/doi.org\/10.1177\/1741134314553606","relation":{},"ISSN":["1741-1343","1741-7090"],"issn-type":[{"type":"print","value":"1741-1343"},{"type":"electronic","value":"1741-7090"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}